Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer: A Stochastic Economic Evaluation

Author： Karnon J.   Brown J.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.2, 2002-02, pp. : 119-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients

By Karnon J.  

PharmacoEconomics, Vol. 21, Iss. 7, 2003-01 ,pp. : 513-525

Adis International

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Tamoxifen plus chemotherapy worth it in early breast cancer?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 354, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Tamoxifen plus chemotherapy worth it in early breast cancer?

By  

Inpharma, Vol. 1, Iss. 1329, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer: Adjuvant Therapy after Administration of Mitomycin

By Ogita M.  

Clinical Drug Investigation, Vol. 23, Iss. 11, 2003-01 ,pp. : 689-699

Adis International

Access to resources Recommend Favorite